Neurocrine Biosciences (NBIX) Short term Debt (2018 - 2024)

Neurocrine Biosciences (NBIX) has reported Short term Debt for 6 consecutive years, with $122.8 million the latest figure, recorded in Q1 2024.

• For the quarter ending Q1 2024, Short term Debt changed N/A year-over-year to $122.8 million; the trailing twelve-month figure through Mar 2024 stood at $122.8 million (changed N/A YoY), and the FY2023 full-year result was $170.1 million, changed 0.41% from the prior year.
• Short term Debt eased to $122.8 million in Q1 2024 per NBIX's latest filing, from $170.1 million in the prior quarter.
• Across five years, Short term Debt topped out at $425.0 million in Q3 2020 and bottomed at $122.8 million in Q1 2024.
• Historically, Short term Debt has averaged $227.0 million across 4 years, with a median of $169.8 million in 2023.
• The widest YoY moves for Short term Debt: up 0.41% in 2023, down 0.41% in 2023.
• Over 4 years, Short term Debt stood at $425.0 million in 2020, then tumbled by 60.14% to $169.4 million in 2022, then advanced by 0.41% to $170.1 million in 2023, then retreated by 27.81% to $122.8 million in 2024.
• According to Business Quant data, Short term Debt over the past three periods registered $122.8 million, $170.1 million, and $169.9 million for Q1 2024, Q4 2023, and Q3 2023 respectively.